Burke Andrew R, DeBold Joseph F, Miczek Klaus A
Department of Psychology, Tufts University, 530 Boston Avenue (Bacon Hall), Medford, MA, 02155, USA.
Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
Psychopharmacology (Berl). 2016 Jul;233(14):2727-36. doi: 10.1007/s00213-016-4336-4. Epub 2016 Jun 1.
Activation of corticotropin-releasing factor type 1 receptors (CRF-R1) in the ventral tegmental area (VTA) represents a critical mechanism for social defeat to escalate cocaine self-administration in adult rats.
We determined the acute effect of a CRF-R1 antagonist (CP376395) microinfusion into the VTA prior to each episode of social defeat in adolescent rats and determined whether this drug treatment could prevent later escalation of cocaine taking in early adulthood.
Rats were implanted with bilateral cannulae aimed at the VTA 5 days before the first social defeat. Bilateral microinfusion of CP376395 (500 ng/side) or vehicle occurred 20 min before each episode of social defeat on postnatal days (P) 35, 38, 41, and 44. Behavior was quantified on P35 and P44. On P57, rats were implanted with intra-jugular catheters, and subsequent cocaine self-administration was analyzed.
CP376395-treated adolescent rats walked less and were attacked more slowly but were socially investigated more than vehicle-treated adolescents. Vehicle-treated rats showed increased social and decreased non-social exploration from P35 to P44, while CP376395-treated rats did not. Socially defeated, vehicle-treated adolescents took more cocaine during a 24-h unlimited access binge during adulthood. The latency to supine posture on P44 was inversely correlated with later cocaine self-administration during fixed and progressive ratio schedules of reinforcement and during the binge.
CP376395 treatment in adolescence blocked escalation of cocaine taking in adulthood. Episodes of social defeat stress engender neuroadaptation in CRF-R1s in the VTA that alter coping with social stress and that persist into adulthood.
腹侧被盖区(VTA)中促肾上腺皮质激素释放因子1型受体(CRF-R1)的激活是成年大鼠社会挫败导致可卡因自我给药升级的关键机制。
我们确定了在青春期大鼠每次社会挫败前向VTA微量注射CRF-R1拮抗剂(CP376395)的急性效应,并确定这种药物治疗是否可以预防成年早期可卡因摄取的后期升级。
在首次社会挫败前5天,给大鼠双侧植入针对VTA的套管。在出生后第(P)35、38、41和44天,每次社会挫败前20分钟双侧微量注射CP376395(500 ng/侧)或赋形剂。在P35和P44对行为进行量化。在P57,给大鼠植入颈内导管,并分析随后的可卡因自我给药情况。
接受CP376395治疗的青春期大鼠走动较少,受到攻击的速度较慢,但比接受赋形剂治疗的青春期大鼠受到更多的社交探究。接受赋形剂治疗的大鼠从P35到P44社交探索增加,非社交探索减少,而接受CP376395治疗的大鼠则没有。在成年期,经历过社会挫败且接受赋形剂治疗的青春期大鼠在24小时无限制获取的暴饮暴食期间摄取了更多可卡因。P44时仰卧姿势的潜伏期与成年期固定和渐进比率强化时间表以及暴饮暴食期间后期的可卡因自我给药呈负相关。
青春期CP376395治疗可阻止成年期可卡因摄取的升级。社会挫败应激事件在VTA的CRF-R1中产生神经适应性变化,改变对社会应激的应对方式,并持续到成年期。